Sarepta Therapeutics Inc. (SRPT) Soars 42.93% on FDA's Elevidys Approval

On July 29, 2025, Sarepta Therapeutics Inc. (SRPT) experienced a remarkable surge, rising 42.93% in pre-market trading, marking a significant milestone for the biopharmaceutical company.

Sarepta's stock price soared following the FDA's decision on Elevidys, a groundbreaking gene therapy for Duchenne muscular dystrophy. This approval has been highly anticipated by investors and the medical community alike, as it represents a major advancement in the treatment of this debilitating disease.

The FDA's decision to approve Elevidys is a testament to Sarepta's commitment to innovation and its dedication to developing life-changing therapies. This approval not only validates the company's research and development efforts but also opens up new opportunities for Sarepta in the gene therapy market.

With the approval of Elevidys, Sarepta is poised to become a leader in the gene therapy space, potentially attracting more investment and partnerships. The company's focus on rare diseases and its innovative approach to drug development have positioned it well to capitalize on this growing market.